Has Bipinkumar Amin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,313,317 in general payments to Bipinkumar Amin, MD across 1,041 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bipinkumar Amin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bipinkumar Amin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bipinkumar Amin, MD

Hematology & Oncology · Watertown, SDNPI 1568415628

Payments from drug & device makers

$1,313,317in general payments, 2019–2025

Across 1,041 payments — averaging $1261.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Beigene, Ltd.$333K
Beone Medicines Ltd.$227K
AstraZeneca$132K
Johnson & Johnson$113K
Bayer$106K
Incyte Corporation$91K
plus $309K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Beigene, Ltd.	56	$333,483
Beone Medicines Ltd.	14	$227,385
AstraZeneca(2 entities)	48	$132,452
Johnson & Johnson(2 entities)	195	$112,765
Bayer	30	$106,402
Incyte Corporation	131	$91,168
Pharmacyclics LLC, An Abbvie Company	146	$81,221
Astrazeneca UK Limited	12	$68,735
Bristol Myers Squibb	59	$53,473
Sanofi	20	$13,312
Geron Corporation	15	$12,834
Karyopharm Therapeutics Inc.	9	$11,725
Amgen	9	$10,483
GSK	11	$8,993
AbbVie	9	$8,554
Ipsen Biopharmaceuticals, Inc	16	$6,928
Sanofi US Services Inc.	2	$4,550
Beigene USA, Inc.	14	$3,747
Pfizer	16	$3,491
Seagen Inc.	17	$3,355
E.r. Squibb & Sons, L.L.C.	6	$3,187
Exelixis Inc.	4	$2,967
Gilead(2 entities)	12	$2,763
Astellas Pharma Global Development	4	$2,016
Janssen Scientific Affairs, LLC	6	$1,520
Coherus Oncology, Inc.	3	$1,178
Astellas Pharma US Inc	10	$1,120
Novartis	24	$424
Daiichi Sankyo Inc.	20	$384
Adaptive Biotechnologies Corporation	3	$272
Tempus AI, Inc	2	$189
Tesaro, Inc.	5	$165
Deciphera Pharmaceuticals Inc.	3	$137
AVEO Pharmaceuticals, Inc.	4	$133
Merck	8	$111
Sanofi-aventis U.S. LLC	2	$105
Regeneron Healthcare Solutions, Inc.	5	$89
Sobi, Inc	3	$83
Eisai Inc.	5	$80
Genentech USA, Inc.	5	$77
Puma Biotechnology, Inc.	5	$72
Lilly USA, LLC	4	$70
Rigel Pharmaceuticals, Inc.	5	$69
Takeda Pharmaceuticals U.S.A., Inc.	4	$61
Octapharma USA, Inc.	3	$60
Acrotech Biopharma Inc.	3	$53
EMD Serono, Inc.	4	$52
Clovis Oncology, Inc.	4	$49
Boehringer Ingelheim	3	$47
Dova Pharmaceuticals	3	$47
Pharmaessentia USA Corporation	2	$41
Genentech, Inc.	1	$40
Teva Pharmaceuticals USA, Inc.	3	$39
Jazz Pharmaceuticals Inc.	2	$39
Progenics Pharmaceuticals, Inc.	2	$36
Helsinn Therapeutics (U.S.), Inc.	3	$35
Beone Medicines USA, Inc.	2	$32
Taiho Oncology, Inc.	2	$32
Myriad Genetic Laboratories, Inc.	2	$31
Mirati Therapeutics, Inc.	2	$30

How this compares

$1,313,317 in reported general payments places this provider in the 80th percentile of 28 hematology & oncology providers in South Dakota.

See all hematology & oncology providers in South Dakota →

Medicare billing

Part B allowed, 2024

$40,493

Medicare patients

157

Services billed

460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Watertown

Vijay RaoWatertown$49K
Ferdinand AddoWatertown$663
Steven PowellSioux Falls$8.5M
Benjamin SolomonSioux Falls$2.8M
Christopher SumeySioux Falls$2.6M
Heidi McKeanSioux Falls$2M
Kelly McCaulSioux Falls$1.5M
Jonathan BleekerSioux Falls$1M
Amy SanfordSioux Falls$837K
Waqas JehangirSioux Falls$698K

See the full list for South Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →